AAFMAA Wealth Management & Trust LLC Buys 717 Shares of Zoetis Inc. (NYSE:ZTS)

AAFMAA Wealth Management & Trust LLC grew its stake in shares of Zoetis Inc. (NYSE:ZTS) by 7.2% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 10,608 shares of the company’s stock after acquiring an additional 717 shares during the quarter. AAFMAA Wealth Management & Trust LLC’s holdings in Zoetis were worth $1,728,000 as of its most recent SEC filing.

Several other large investors have also recently modified their holdings of ZTS. Darwin Wealth Management LLC purchased a new position in Zoetis in the third quarter worth about $31,000. First Personal Financial Services purchased a new position in Zoetis in the 3rd quarter worth approximately $33,000. Capital Performance Advisors LLP bought a new position in Zoetis in the 3rd quarter valued at approximately $33,000. Dunhill Financial LLC boosted its stake in Zoetis by 80.6% during the 3rd quarter. Dunhill Financial LLC now owns 168 shares of the company’s stock valued at $33,000 after purchasing an additional 75 shares during the last quarter. Finally, Quarry LP increased its holdings in shares of Zoetis by 273.2% in the 2nd quarter. Quarry LP now owns 209 shares of the company’s stock worth $36,000 after purchasing an additional 153 shares in the last quarter. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Zoetis Stock Performance

Shares of NYSE ZTS opened at $166.31 on Tuesday. The company has a debt-to-equity ratio of 1.26, a current ratio of 3.69 and a quick ratio of 2.27. Zoetis Inc. has a 1 year low of $144.80 and a 1 year high of $200.53. The firm has a fifty day moving average price of $171.53 and a 200-day moving average price of $180.22. The stock has a market cap of $75.03 billion, a PE ratio of 31.26, a price-to-earnings-growth ratio of 2.91 and a beta of 0.89.

Zoetis (NYSE:ZTS) last announced its quarterly earnings data on Monday, November 4th. The company reported $1.58 EPS for the quarter, beating the consensus estimate of $1.46 by $0.12. The business had revenue of $2.40 billion for the quarter, compared to the consensus estimate of $2.29 billion. Zoetis had a return on equity of 51.98% and a net margin of 26.55%. The business’s revenue was up 11.6% on a year-over-year basis. During the same period in the previous year, the business earned $1.36 earnings per share. Equities analysts anticipate that Zoetis Inc. will post 5.9 earnings per share for the current fiscal year.

Zoetis Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, March 4th. Investors of record on Tuesday, January 21st will be given a dividend of $0.50 per share. This is a positive change from Zoetis’s previous quarterly dividend of $0.43. The ex-dividend date of this dividend is Tuesday, January 21st. This represents a $2.00 dividend on an annualized basis and a dividend yield of 1.20%. Zoetis’s dividend payout ratio is currently 37.59%.

Analyst Ratings Changes

A number of brokerages have recently issued reports on ZTS. Leerink Partners started coverage on Zoetis in a report on Monday, December 2nd. They set an “outperform” rating and a $215.00 price target on the stock. JPMorgan Chase & Co. lifted their price target on shares of Zoetis from $225.00 to $230.00 and gave the stock an “overweight” rating in a research note on Friday, October 11th. Leerink Partnrs upgraded shares of Zoetis to a “strong-buy” rating in a report on Monday, December 2nd. Stifel Nicolaus lowered their price target on Zoetis from $210.00 to $180.00 and set a “buy” rating on the stock in a report on Tuesday, January 7th. Finally, UBS Group assumed coverage on Zoetis in a report on Monday, December 9th. They issued a “neutral” rating and a $196.00 price objective for the company. One equities research analyst has rated the stock with a hold rating, nine have issued a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus target price of $211.89.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.